A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2013
At a glance
- Drugs TAK 583 (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 15 Oct 2008 New trial record.